Immunology Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
Laboratory of Genetics and Molecular Basis of Complex Diseases, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, IdISSC, Madrid, Spain.
J Nephrol. 2023 Apr;36(3):809-815. doi: 10.1007/s40620-022-01419-5. Epub 2022 Aug 10.
A genome-wide association study (GWAS) in kidney transplant recipients reported the association of two polymorphisms located in the PTPRO gene and upstream of the CCDC67 (DEUP1) gene with increased risk of acute T cell-mediated rejection (TCMR). We aimed at replicating the assessment of mentioned associations and additionally ascertaining the influence of treatment and clinical features of the patients.
The polymorphisms, PTPRO-rs7976329 and CCDC67-rs10765602 were genotyped by TaqMan chemistry in 641 consecutive kidney transplant recipients. The diagnosis of rejection was confirmed by biopsy and categorized according to the Banff classification. Associations were evaluated by Chi-square test or Fisher's exact test when necessary and multivariate logistic regression.
Considering the GWAS study we only replicated the association of the PTPRO-rs7976329*C allele in the Banff grade < II subjects. However, the homozygous mutant genotypes of both polymorphism seemed to increase the risk of TCMR Banff grade < II in the overall cohort and after stratification by Thymoglobulin induction therapy. In the multivariate analysis, we confirmed the association of PTPRO-rs7976329 with TCMR Banff grade < II, independently of the Thymoglobulin induction therapy and of CCDC67-rs10765602 only in the group of patients not receiving Thymoglobulin induction therapy. No association of these polymorphisms with TCMR Banff grade ≥ II was observed in either the overall cohort or in the subgroups stratified by Thymoglobulin therapy.
Our study shows that the increased risk of TCMR related to polymorphisms PTPRO-rs7976329 and CCDC67-rs10765602 previously reported in a GWAS was replicated only in homozygous patients who presented TCMR Banff grade < II and for the minor allele of either polymorphism.
一项针对肾移植受者的全基因组关联研究(GWAS)报告了位于 PTPRO 基因内和 CCDC67(DEUP1)基因上游的两个多态性与急性 T 细胞介导的排斥反应(TCMR)风险增加相关。我们旨在复制评估上述关联,并进一步确定患者治疗和临床特征的影响。
通过 TaqMan 化学法在 641 例连续肾移植受者中对多态性 PTPRO-rs7976329 和 CCDC67-rs10765602 进行基因分型。通过活检确认排斥反应的诊断,并根据 Banff 分类进行分类。当需要时,通过卡方检验或 Fisher 确切检验评估关联,并进行多变量逻辑回归。
考虑到 GWAS 研究,我们仅复制了 PTPRO-rs7976329*C 等位基因在 Banff 分级< II 患者中的关联。然而,两种多态性的纯合突变基因型似乎增加了总体队列和 Thymoglobulin 诱导治疗分层后的 TCMR Banff 分级< II 的风险。在多变量分析中,我们确认了 PTPRO-rs7976329 与 TCMR Banff 分级< II 的关联,独立于 Thymoglobulin 诱导治疗,并且仅在未接受 Thymoglobulin 诱导治疗的患者组中与 CCDC67-rs10765602 相关。在总体队列或 Thymoglobulin 治疗分层的亚组中,均未观察到这些多态性与 TCMR Banff 分级≥ II 的关联。
我们的研究表明,GWAS 中先前报道的与 PTPRO-rs7976329 和 CCDC67-rs10765602 多态性相关的 TCMR 风险增加仅在表现为 TCMR Banff 分级< II 的纯合患者中和两种多态性的次要等位基因中复制。